93 related articles for article (PubMed ID: 29661724)
21. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.
Przybycin CG; Cronin AM; Darvishian F; Gopalan A; Al-Ahmadie HA; Fine SW; Chen YB; Bernstein M; Russo P; Reuter VE; Tickoo SK
Am J Surg Pathol; 2011 Jul; 35(7):962-70. PubMed ID: 21602658
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features on chromophobe renal cell carcinoma].
Wang ZH; DU LH; Hu ZQ; Chen XG; Zhao X; Wang SG; Zhuang QY; Ye ZQ
Zhonghua Wai Ke Za Zhi; 2011 Apr; 49(4):320-3. PubMed ID: 21612697
[TBL] [Abstract][Full Text] [Related]
23. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
Takamori S; Takada K; Toyokawa G; Azuma K; Shimokawa M; Jogo T; Yamada Y; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5897-5901. PubMed ID: 30275216
[TBL] [Abstract][Full Text] [Related]
24. New cut-off point between T1 and T2 renal cell carcinoma - necessary for a better discriminatory power of the TNM classification.
Wunderlich H; Dreihaupt M; Schlichter A; Kosmehl H; Reichelt O; Schubert J
Urol Int; 2004; 72(2):123-8. PubMed ID: 14963352
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
26. The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases.
Zhang C; Li X; Hao H; Yu W; He Z; Zhou L
BJU Int; 2012 Dec; 110(11 Pt B):E481-5. PubMed ID: 22540142
[TBL] [Abstract][Full Text] [Related]
27. Cytohistological study of clear cell carcinoma of kidney with special reference to nuclear grading and tumor size.
Mondal SK
Diagn Cytopathol; 2012 Dec; 40(12):1083-7. PubMed ID: 21563327
[TBL] [Abstract][Full Text] [Related]
28. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor.
Aron M; Chang E; Herrera L; Hes O; Hirsch MS; Comperat E; Camparo P; Rao P; Picken M; Michal M; Montironi R; Tamboli P; Monzon F; Amin MB
Am J Surg Pathol; 2015 Jul; 39(7):873-88. PubMed ID: 25970682
[TBL] [Abstract][Full Text] [Related]
29. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
[TBL] [Abstract][Full Text] [Related]
31. Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature.
Peckova K; Martinek P; Ohe C; Kuroda N; Bulimbasic S; Condom Mundo E; Perez Montiel D; Lopez JI; Daum O; Rotterova P; Kokoskova B; Dubova M; Pivovarcikova K; Bauleth K; Grossmann P; Hora M; Kalusova K; Davidson W; Slouka D; Miroslav S; Buzrla P; Hynek M; Michal M; Hes O
Ann Diagn Pathol; 2015 Aug; 19(4):261-8. PubMed ID: 26031603
[TBL] [Abstract][Full Text] [Related]
32. Small renal tumors: correlation of clinical and pathological features with tumor size.
Pahernik S; Ziegler S; Roos F; Melchior SW; Thüroff JW
J Urol; 2007 Aug; 178(2):414-7; discussion 416-7. PubMed ID: 17561161
[TBL] [Abstract][Full Text] [Related]
33. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
34. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
35. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
36. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases.
Ficarra V; Righetti R; Martignoni G; D'Amico A; Pilloni S; Rubilotta E; Malossini G; Mobilio G
Urol Int; 2001; 67(2):130-4. PubMed ID: 11490206
[TBL] [Abstract][Full Text] [Related]
38. Value of nuclear morphometry for differentiating localized from metastatic renal cell carcinoma.
Nativ O; Sabo E; Raviv G; Halachmi S; Moskovitz B
Eur Urol; 1998; 33(2):186-9. PubMed ID: 9519362
[TBL] [Abstract][Full Text] [Related]
39. Tumour necrosis in chromophobe renal cell carcinoma: clinical data to distinguish aggressive variants.
Zini L; Leroy X; Lemaitre L; Devos P; Aubert S; Biserte J; Villers A
Eur J Surg Oncol; 2008 Jun; 34(6):687-91. PubMed ID: 17997271
[TBL] [Abstract][Full Text] [Related]
40. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.
Delahunt B; McKenney JK; Lohse CM; Leibovich BC; Thompson RH; Boorjian SA; Cheville JC
Am J Surg Pathol; 2013 Mar; 37(3):311-22. PubMed ID: 23348209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
